EBS Long Call Strategy

EBS (Emergent BioSolutions Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions.

EBS (Emergent BioSolutions Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $440.1M, a beta of 2.33 versus the broader market, a 52-week range of 5.62-14.06, average daily share volume of 817K, a public-listing history dating back to 2006, approximately 900 full-time employees. These structural characteristics shape how EBS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.33 indicates EBS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on EBS?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current EBS snapshot

As of June 30, 2026, spot at $8.46, ATM IV 66.10%, IV rank 4.25%, expected move 18.95%. The long call on EBS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this long call structure on EBS specifically: EBS IV at 66.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a EBS long call, with a market-implied 1-standard-deviation move of approximately 18.95% (roughly $1.60 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EBS expiries trade a higher absolute premium for lower per-day decay. Position sizing on EBS should anchor to the underlying notional of $8.46 per share and to the trader's directional view on EBS stock.

EBS long call setup

The EBS long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EBS near $8.46, the first option leg uses a $8.46 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EBS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EBS shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$8.46N/A

EBS long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

EBS long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on EBS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on EBS

Long calls on EBS express a bullish thesis with defined risk; traders use them ahead of EBS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

EBS thesis for this long call

The market-implied 1-standard-deviation range for EBS extends from approximately $6.86 on the downside to $10.06 on the upside. A EBS long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current EBS IV rank near 4.25% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EBS at 66.10%. As a Healthcare name, EBS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EBS-specific events.

EBS long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EBS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EBS alongside the broader basket even when EBS-specific fundamentals are unchanged. Long-premium structures like a long call on EBS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current EBS chain quotes before placing a trade.

Frequently asked questions

What is a long call on EBS?
A long call on EBS is the long call strategy applied to EBS (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With EBS stock trading near $8.46, the strikes shown on this page are snapped to the nearest listed EBS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are EBS long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the EBS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 66.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a EBS long call?
The breakeven for the EBS long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EBS market-implied 1-standard-deviation expected move is approximately 18.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on EBS?
Long calls on EBS express a bullish thesis with defined risk; traders use them ahead of EBS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current EBS implied volatility affect this long call?
EBS ATM IV is at 66.10% with IV rank near 4.25%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related EBS analysis